TheraRadar
← Back
Data updated: Mar 29, 2026

HANGZHOU ZHONGMEI

MetabolicInfectious DiseaseDermatology
Generics

HANGZHOU ZHONGMEI is a generic drug manufacturer focused on Metabolic, Infectious Disease, Dermatology.

2020
Since
6
Drugs
-
Trials
82
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
TACROLIMUS 2025-10-17
Labeling
TACROLIMUS 2025-10-17
Labeling
TACROLIMUS 2025-10-17
Labeling
TACROLIMUS 2025-10-17
Labeling
PANTOPRAZOLE SODIUM 2025-10-15
Labeling
PANTOPRAZOLE SODIUM 2025-10-15
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 58%
1 drugs Phase 3: 8 Phase 2: 4 Phase 1: 5
Infectious Disease 14%
2 drugs
Dermatology 11%
1 drugs Phase 3: 1
Immunology 9%
0 drugs Phase 3: 2
Oncology 8%
0 drugs Phase 1: 7

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology
Merck big-pharma
Oncology, Infectious Disease, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Immunology
Eli Lilly big-pharma
Metabolic, Oncology, Immunology, Dermatology